Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses

D’Ascenzo, Fabrizio; Bollati, Mario; Clementi, Fabrizio; Castagno, Davide; Lagerqvist, Bo; Hernández, José M. de la Torre; Berg, J. M. ten; Brodie, Bruce R.; Urban, Philip; Jensen, Lisette Okkels; Sardi, Gabriel; Waksman, Ron; Lasala, John M.; Schulz, Stefanie; Stone, Gregg W.; Airoldi, Flavio; Colombo, Antonio; Lemesle, Gilles; Applegate, Robert J.; Buonamici, Piergiovanni; Kirtane, Ajay J.; Undas, Anetta; Sheiban, Imad; Gaïta, Fiorenzo; Sangiorgi, Giuseppe; Modena, Maria Grazia; Frati, Giacomo; Biondi‐Zoccai, Giuseppe

doi:10.1016/j.ijcard.2012.01.080

Cited by 168 publications

(103 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ST occurred more frequently in the subgroup of patients without postdilatation. ST represents an important issue in the ACS setting as it is potentially triggered by enhanced aggregation of platelets [34]. BRS represents a potential risk for scaffold thrombosis because of the relatively thick struts and limited expansion.…”

Section: Discussionmentioning

confidence: 99%

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter “real-world” registry

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background: Safety and efficacy of bioresorbable vascular scaffolds (BRS) and the role of postdilatation on outcome in acute coronary syndrome (ACS) patients compared with those of everolimus-eluting stents (EES) remain unknown. The aim of the study is to compare the safety and efficacy of BRS with EES in ACS and without, comparable to EES patients (6.0% vs. 12.6% vs. 4.7%, p < 0.001). The same trend was observed for TLR (3.4% vs. 8.4% vs. 1.9%, p < 0.001 (Cardiol J 2016; 23, 4: 374-383)

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter “real-world” registry

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 A meta-analysis found that the risk of stent thrombosis was highest in the setting of extensive CAD, early discontinuation of DAPT, and number of stents 4 with these risk factors alone, the patient was already at higher risk for a negative outcome.…”

Section: "There Is No Disease More Conducive To Clinical Humility Thamentioning

confidence: 99%

Inferior STEMI Complicated by Retroperitoneal Hemorrhage due to Ruptured AAA

III¹,

Lester²,

Chowdhury³

2017

mjm

View full text Add to dashboard Cite

“…The choice of antiplatelet agents and duration of antiplatelet therapy after ACS may be influenced by the presence of risk factors for stent thrombosis [28] and the type of management used (medical treatment with or without delayed angiography, acute or emergent PCI, CABG) [29,30].…”

Section: Indications and Guidelines On Myocardial Revascularizationmentioning

confidence: 99%

How to manage prasugrel and ticagrelor in daily practice

Bonhomme¹,

Fontana²,

Reny³

2014

European Journal of Internal Medicine

View full text Add to dashboard Cite

Prasugrel and ticagrelor are next-generation antiplatelet agents that provide a rapider and more potent inhibition of platelet P2Y12 receptor than clopidogrel. In combination with aspirin, these new P2Y12 inhibitors are now the first line treatments for patients with acute coronary syndrome. However, these potent antiplatelet agents introduce a new paradigm in the daily management of antithrombotic drugs, particularly when an invasive procedure is planned. The pharmacology of these antiplatelet agents, and the results of the main clinical trials, are reviewed with a special focus on good prescription practices (indications, contra-indications, drug interactions), and on peri-operative management. Strategies are proposed for safely reducing the bleeding risk in elderly patients, in patients requiring concomitant oral anticoagulant therapy, or in patients with an increased haemorrhagic risk.

show abstract

Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses

Abstract: Despite numerous possible risk factors, the most common and consistent predictors of stent thrombosis are early antiplatelet therapy discontinuation, extent of coronary disease, and stent number/length.

Cited by 168 publications

References 95 publications

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter “real-world” registry

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter “real-world” registry

Inferior STEMI Complicated by Retroperitoneal Hemorrhage due to Ruptured AAA

How to manage prasugrel and ticagrelor in daily practice

Contact Info

Product

Resources

About